Gateway-funded trial successfully using, for the first time, a form of immunotherapy called CAR-T to harness a patient's own immune system to treat aggressive glioblastoma brain tumors.
Pancreatic adenocarcinoma trial showing early promise, evaluating the benefits of a molecular therapy with epigenetic modulating drugs, with the goal of seeing a reduced recurrence of pancreatic cancer and an improved quality of life with reduced side effects for cancer survivors.
"Tumor Paint" discovery being researched, using a peptide found in the venom of a scorpion, which attaches to tumor tissue and glows under fluorescent light, making it easier for pediatric brain surgeons to better target cancer tissue.
Evaluating use of a plant-based substance to fight post-chemotherapy cognitive impairment in breast cancer patients, and is one of the first studies of its kind that could benefit patients with "chemo-brain."
Gateway for Cancer Research℠ is a 501(c)(3) nonprofit organization committed to funding innovative cancer research that helps people living with cancer to feel better, live longer and conquer cancer TODAY!
CTCA, through Gateway, has made a tremendous commitment to funding research benefiting all patients regardless of where they are treated, including at many of the top cancer centers in the U.S. and abroad. Thanks to generous underwriting by CTCA, 99 cents of every dollar Gateway receives directly funds Phase I and Phase II cancer clinical trials.
In its 26 year history more than 150 trials in early phase cancer research have been funded by Gateway, where funding is most needed, helping to improve the standard of care for courageous patients worldwide.
Stay up to date with latest research, studies and news.